Pharmascience Invests $120 Million to Expand Sterile Injectable Manufacturing Unit in Canada

Specifications:

Name:

Pharmascience Invests $120 Million to Expand Sterile Injectable Manufacturing Unit in Canada

Location:

Canada

Company:

Pharmascience

Estimated Cost:

$120 Million

Source:

https://www.pharmascience.com

Introduction:

Pharmascience, the largest Canadian-owned pharmaceutical company, announced a major $120 million sterile injectable manufacturing facility expansion at its Candiac site.

Features:

The facility aims to triple the current capacity, enabling it to serve a larger patient population by expanding its facilities and upgrading equipment with cutting-edge technology. Annual production is anticipated to surpass 20 million units as a result.

With a specialised focus on injectable products, the unit will prioritise offering CDMO services to biotech firms and entities with intricate requirements for injectable product development or manufacturing.

The new business unit is poised to expedite production and fulfil growth targets by facilitating the provision of its R&D, formulation, and manufacturing services to external pharmaceutical partners.

The expansion is currently underway and will position to compete on a global scale, while also broadening its client base with a variety of new products and services.

The new CDMO business unit signifies a strategic approach to optimising the value derived from research and development endeavours, as well as from each unit manufactured at Candiac plant.

It is expected to be completely by 2026.